Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients (DOLAVI)
Sponsor: University Hospital Virgen de las Nieves
Listed as NCT04002323, this observational or N/A phase trial focuses on HIV-1-infection and remains completed. Sponsored by University Hospital Virgen de las Nieves, it has been updated 8 times since 2019, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Aug 2024 — Sep 2024 [monthly]
Completed
Status: Unknown → Completed
-
Jul 2024 — Aug 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Aug 2019 — Jan 2021 [monthly]
Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Recruiting
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Virgen de las Nieves
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almería, Spain , Cadiz, Spain , Córdoba, Spain , El Palmar, Spain , Granada, Spain , Jaén, Spain , Las Palmas de Gran Canaria, Spain , Logroño, Spain , Madrid, Spain , Melilla, Spain and 7 more locations